MESOBLAST LIMITED (ASX:MSB) - MSB Trading - 2020, 42470242, page-723 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by stockrock ↑

From a business standpoint, if approved, Ryoncil will be the lifeline that Mesoblast requires to fund its operations for the foreseeable future... with Mesoblast taking on debt, those interest repayments will be growing for some time yet, but there will be a genuine on-going revenue source that Mesoblast can depend on to service that debt. So the program is not only going to save many children's lives from 2020... it will literally save Mesoblast's corporate life.

If Mesoblast does one day succeed commercially and realises its full potential... we will have to thank Ryoncil for making it all possible.

But having a look at what lies ahead in 2020 and 2021, we know that Mesoblast is already building its distribution network for paediatric aGHVD sufferers... with the large majority of patient concentration skewed to a dozen or so centres in the US.. this has allowed Mesoblast to potentially bring Ryoncil to the US market itself, thus retaining 100% of the sales proceeds (this is rare). All the centres in the trial already know the product and its efficacy was witnessed first hand... in fact, the practitioners themselves have been waiting for Ryoncil to be approved so they can immediately offer it to their patients. As far as I know, only those in the EAP and the phase 3 trial were offered Ryoncil... since the end of the phase 3 trial, patients have been deprived of it.

There is talk about what Ryoncil may also be used for... but in reality, those applications will take many more years to develop in the clinic. What we know for sure is that adult aGVHD is a natural label extension after the approval of Ryoncil. The adult aGHVD market is larger and less concentrated, as such a partner will be required for Mesoblast to unlock that revenue stream. The partner will need to fund a trial (or Mesoblast could go ahead and do it itself), and then take on the registration and marketing/distribution of the product. If Ryoncil is approved, this is a real no brainer- for a Pharma coy in the US to quickly snap this up.

What a year we have ahead for us... there will be ups and downs in the coming months, but ultimately the clinical trial results will define Mesoblast's trajectory in the foreseeable future. I have been waiting for this period in Mesoblast's corporate life for a very long time.

Some significant events in human history are well known and have had very public lead ups... just look at SpaceX, they are about to embark on some significant steps in advancing human's reach in this solar system. A paradigm shift in space travel. Other significant events in human history are less known and happen behind doors, or in this case.. in laboratories and clinics. In that same vein of thought, as others have already expressed a similar thought.. I echo how lucky I feel to be able to be part of Mesoblast's journey so far, as I have no doubt that if the upcoming trials are successful for chronic lower back pain and chronic heart failure (we will know results of both by mid 2020)... we are all here witnessing a paradigm shift in the pharmaceutical industry. How bloody fantastic that will be.

Expand

The adult aGHVD market is larger and less concentrated, as such a partner will be required for Mesoblast to unlock that revenue stream.

IMO @stockrock this could be the next partnership announcement ..... there would have to be players sniffing around for this as we speak given the progress for the ?

Don't forget what @ecoool2 said in this post about ASX200 :

https://hotcopper.com.au/threads/msb-trading-2019.4593749/page-2522?post_id=40425160

If MSB starts looking like a possibility for ASX200 Index inclusion by March next year, some funds will start buying a month or so ahead, while others will have to wait for the official announcement. In a thinly traded stock, this should provide plenty of upside.

Makes me wonder if this has already started ? Just my opinion though

A close above $2.70 today will make me more than happy.

GLTAH

No.	Vol.	Price($)
5	79396	$1.10

No.

Vol.

Price($)

79396

$1.10

Price($)	Vol.	No.
$1.11	60351	4

Price($)

Vol.

No.

$1.11

60351

No.	Vol.	Price($)
1	1000	1.200
2	6476	1.130
4	7300	1.120
4	32000	1.110
6	30367	1.105

No.

Vol.

Price($)

1000

1.200

6476

1.130

7300

1.120

32000

1.110

30367

1.105

Price($)	Vol.	No.
1.045	56335	3
1.070	2874	3
1.080	26060	2
1.090	5000	1
1.100	38300	5

Price($)

Vol.

No.

1.045

56335

1.070

2874

1.080

26060

1.090

5000

1.100

38300

(20min delay)
Last $1.10		Change 0.110(11.1%)		Mkt cap ! $1.255B

Open	High	Low	Value	Volume
97.0¢	$1.11	95.5¢	$15.75M	15.06M


Last $1.10		Change 0.110 ( 10.8 %)
Open	High	Low	Volume
96.5¢	$1.11	95.5¢	2700730
Last updated 15.59pm 01/05/2024 ?

The adult aGHVD market is larger and less concentrated, as such...

Featured News

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Recharged Prospects: 'Watts' on the horizon for copper & lithium

Carnarvon revs up for revised Dorado Development

Provident Aurum's off-market bid sends Sihayo shares soaring

Buyers (Bids)

Sellers (Offers)

Featured News

The adult aGHVD market is larger and less concentrated, as such...

Featured News

Top Stories

Why Princeton Professor rates BlinkLab's autism & ADHD screening app

Lithium Universe ends the quarter charged up for Quebec Refinery roll-out

Recharged Prospects: 'Watts' on the horizon for copper & lithium

Carnarvon revs up for revised Dorado Development

Provident Aurum's off-market bid sends Sihayo shares soaring

Buyers (Bids)

Sellers (Offers)

Featured News